The litigation centers on claims that ARS Pharmaceuticals violated the Securities Exchange Act of 1934 by issuing false or misleading statements. According to the complaint, the company allegedly ignored or recklessly disregarded significant risks involving CVS Caremark’s integration of its product, neffy, into their formulary. This oversight reportedly created uncertainty regarding insurance coverage, which directly impacted the company's financial outlook and share price.

Investors who suffered losses during this window have until October 5, 2026, to participate in the legal proceedings. While the class has not yet been certified, those interested in discussing their rights or the potential for recovery are encouraged to contact attorneys Brian Schall or David Schwartz at the Los Angeles-based firm. Participation as a lead plaintiff is not a prerequisite for recovering damages, and shareholders who choose not to act remain absent class members until formal certification occurs.